Table 2.
Characteristics of patients treated with CDK4/6is plus ET.
| Treatment characteristic | CDK4/6is + ET, n = 2249 | ||
|---|---|---|---|
| IDC, n = 1834 (81%) | ILC, n = 336 (15%) | Mixed, n = 79 (4%) | |
| CDK4/6is, n (%) | |||
| Palbociclib | 1709 (93) | 310 (92) | 74 (94) |
| Ribociclib | 51 (3) | 5 (2) | 2 (3) |
| Abemaciclib | 74 (4) | 21 (6) | 3 (4) |
| Line of therapy, n (%) | |||
| 1L | 1245 (68) | 248 (74) | 58 (73) |
| 2L+ | 589 (32) | 88 (26) | 21 (27) |
| ET backbone in 1L, n (%) | |||
| Aromatase inhibitor | 829 (67) | 158 (64) | 34 (59) |
| Fulvestrant | 416 (33) | 90 (36) | 24 (41) |
CDK4/6is cyclin-dependent kinase 4 and 6 inhibitors, ET endocrine therapy, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, mixed mixed invasive ductal and lobular carcinoma, 1L first line, 2L+ second line and beyond.